Calculate the Scoring Atopic Dermatitis (SCORAD) index to review eczema extent, intensity, and symptom burden in one severity worksheet.
The Scoring Atopic Dermatitis (SCORAD) index is the most widely used clinical tool for assessing the severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis, it combines three components: disease extent (percentage of body surface area affected), clinical intensity (six observable signs), and subjective symptoms (pruritus and sleep disturbance).
The SCORAD formula — A/5 + 7B/2 + C — weights intensity most heavily (maximum 63 points from the B component), reflecting the clinical importance of lesion severity. Scores range from 0 to 103, classified as mild (< 25), moderate (25–50), or severe (> 50). This three-category classification directly maps to treatment algorithms in international guidelines (EAACI, AAD, BAD).
In clinical practice, SCORAD is used for initial severity assessment, treatment step selection, disease monitoring over time, clinical trial endpoints, and insurance pre-authorization for biologic therapies. The Objective SCORAD (excluding subjective symptoms) is preferred in research settings where patient-reported outcomes may introduce variability.
SCORAD is useful when disease severity needs to be described in a reproducible way rather than as a loose impression. It keeps extent, visible inflammation, and symptom burden on the same scale so eczema severity can be tracked over time or discussed consistently across visits.
SCORAD = A/5 + 7B/2 + C A = Extent (0–100% BSA) B = Intensity (6 items × 0–3 each = 0–18) C = Subjective symptoms (pruritus 0–10 + sleep loss 0–10 = 0–20) Max SCORAD = 100/5 + 7×18/2 + 20 = 20 + 63 + 20 = 103
Result: SCORAD = 24.0 (Mild), Objective SCORAD = 16.0
Extent (A) = 15% BSA, contributing 3.0 points. Intensity (B) = 4/18, contributing 14.0 points (the dominant component). Subjective (C) = 8/20, contributing 8.0 points. Total SCORAD = 3 + 14 + 8 = 25.0. This is at the mild-moderate boundary — regular emollients with topical corticosteroids for flares.
SCORAD combines how much skin is involved, how inflamed the lesions look, and how disruptive the symptoms feel to the patient. That three-part structure is why it can look different from purely clinician-scored tools such as EASI.
Separating the objective component can help when itch and sleep loss fluctuate for reasons that are not fully visible on the skin exam. Looking at both numbers together often gives a clearer picture than using either one alone.
The score is most helpful for serial follow-up, trial-style documentation, and communicating severity in a consistent way. It works best when it supports the clinical review instead of being treated as the entire treatment decision.
Last updated:
This calculator applies the published SCORAD formula by combining extent, six clinician-scored intensity signs, and two patient-reported symptom scores. It also shows the objective SCORAD so the observable disease burden can be reviewed separately from itch and sleep-loss ratings when that distinction is useful.
The score is intended to standardize severity review. It does not prescribe treatment on its own, because location, infection, prior treatment response, and the broader dermatitis history still matter.
SCORAD includes subjective symptoms (pruritus, sleep loss) while EASI (Eczema Area and Severity Index) is entirely clinician-assessed. EASI is more commonly used in clinical trials; SCORAD is more common in clinical practice because it captures patient experience. Both are validated.
The Minimal Clinically Important Difference (MCID) for SCORAD is approximately 8.7 points. A decrease of this magnitude represents a meaningful improvement that patients and clinicians can perceive. For Objective SCORAD, the MCID is approximately 6.6 points.
The B component (intensity) can contribute up to 63 of the maximum 103 points because clinical lesion severity most directly impacts treatment decisions. A patient with 10% BSA involvement but severe oozing and excoriation needs more aggressive treatment than someone with 30% BSA of mild dryness.
Dryness is assessed on uninvolved (non-lesional) skin only, as involved skin may have multiple overlapping signs. Rate dryness 0-3 on typical unaffected skin: 0 = normal, 1 = slight roughness, 2 = rough with visible scaling, 3 = severe cracking.
Yes, but the visual analog scales (pruritus, sleep loss) can be challenging for young children. Parents can report on behalf of children under 7. For infants, clinician-assessed scores (Objective SCORAD) may be more reliable.
A SCORAD increase of > 8.7 points (the MCID) on current therapy suggests treatment failure. Persistent SCORAD ≥ 50 despite moderate-potency topical therapy or SCORAD ≥ 25 despite optimal topical management may warrant systemic therapy consideration.